Company / R&D Expense
Editas Medicine, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$199.2M
FY2025
5-year range
$96.9M / $199.2M
FY2021-FY2025
Trend
+13.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $143M to $199M over the past 2 years.
Based on SEC 10-K filings.
$199M in FY2025 with a 5-year CAGR of +17.1%.
Improved from $143M to $199M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +8.0%
- 5-Year CAGR
- +17.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +17.1%, indicating consistent growth.
- In FY2025, r&d expense increased 13.9% year-over-year.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $199.2M | +13.9% |
| FY2024 | $175.0M | +22.8% |
| FY2023 | $142.5M | -9.8% |
| FY2022 | $158.0M | +63.1% |
| FY2021 | $96.9M | +6.9% |
| FY2020 | $90.7M | +9.0% |
| FY2019 | $83.2M | +45.9% |
| FY2018 | $57.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026